Literature DB >> 23672312

Guidelines and considerations for conducting experiments using tissue microarrays.

Mohammad Ilyas1, Heike Grabsch, Ian O Ellis, Chris Womack, Robert Brown, Dan Berney, Dean Fennell, Manuel Salto-Tellez, Martin Jenkins, Goran Landberg, Richard Byers, Darren Treanor, David Harrison, Andrew R Green, Graham Ball, Peter Hamilton.   

Abstract

Tissue microarrays (TMAs) represent a powerful method for undertaking large-scale tissue-based biomarker studies. While TMAs offer several advantages, there are a number of issues specific to their use which need to be considered when employing this method. Given the investment in TMA-based research, guidance on design and execution of experiments will be of benefit and should help researchers new to TMA-based studies to avoid known pitfalls. Furthermore, a consensus on quality standards for TMA-based experiments should improve the robustness and reproducibility of studies, thereby increasing the likelihood of identifying clinically useful biomarkers. In order to address these issues, the National Cancer Research Institute Biomarker and Imaging Clinical Studies Group organized a 1-day TMA workshop held in Nottingham in May 2012. The document herein summarizes the conclusions from the workshop. It includes guidance and considerations on all aspects of TMA-based research, including the pre-analytical stages of experimental design, the analytical stages of data acquisition, and the postanalytical stages of data analysis. A checklist is presented which can be used both for planning a TMA experiment and interpreting the results of such an experiment. For studies of cancer biomarkers, this checklist could be used as a supplement to the REMARK guidelines.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23672312     DOI: 10.1111/his.12118

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  25 in total

1.  EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Authors:  Timothy D Clay; Prudence A Russell; Hongdo Do; Vijaya Sundararajan; Matthew Conron; Gavin M Wright; Benjamin Solomon; Alexander Dobrovic; Sue-Anne McLachlan; Melissa M Moore
Journal:  Med Oncol       Date:  2017-09-06       Impact factor: 3.064

2.  Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma.

Authors:  Enken Drecoll; Ulrich Nitsche; Karina Bauer; Sabina Berezowska; Julia Slotta-Huspenina; Robert Rosenberg; Rupert Langer
Journal:  Int J Colorectal Dis       Date:  2014-04-15       Impact factor: 2.571

3.  FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.

Authors:  Guy Betts; Helen Valentine; Sue Pritchard; Richard Swindell; Victoria Williams; Shethah Morgan; Ewen A Griffiths; Ian Welch; Catharine West; Christopher Womack
Journal:  Virchows Arch       Date:  2013-12-04       Impact factor: 4.064

4.  Simple method for constructing and repairing tissue microarrays using simple equipment.

Authors:  Wei Zhang; Fuman Qiu; Qingping Jiang; Shaoyan Liu; Zhongtang Xiong
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 5.  Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.

Authors:  Jan Stenvang; Iben Kümler; Sune Boris Nygård; David Hersi Smith; Dorte Nielsen; Nils Brünner; José M A Moreira
Journal:  Front Oncol       Date:  2013-12-25       Impact factor: 6.244

Review 6.  Tissue fixation and the effect of molecular fixatives on downstream staining procedures.

Authors:  William J Howat; Beverley A Wilson
Journal:  Methods       Date:  2014-02-21       Impact factor: 3.608

7.  Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.

Authors:  Sabina Berezowska; Alexander Novotny; Karina Bauer; Annette Feuchtinger; Julia Slotta-Huspenina; Karen Becker; Rupert Langer; Axel Walch
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240

8.  Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers.

Authors:  William J Howat; Arthur Lewis; Phillipa Jones; Caroline Kampf; Fredrik Pontén; Chris M van der Loos; Neil Gray; Chris Womack; Anthony Warford
Journal:  Methods       Date:  2014-02-11       Impact factor: 3.608

9.  Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium.

Authors:  William J Howat; Fiona M Blows; Elena Provenzano; Mark N Brook; Lorna Morris; Patrycja Gazinska; Nicola Johnson; Leigh-Anne McDuffus; Jodi Miller; Elinor J Sawyer; Sarah Pinder; Carolien H M van Deurzen; Louise Jones; Reijo Sironen; Daniel Visscher; Carlos Caldas; Frances Daley; Penny Coulson; Annegien Broeks; Joyce Sanders; Jelle Wesseling; Heli Nevanlinna; Rainer Fagerholm; Carl Blomqvist; Päivi Heikkilä; H Raza Ali; Sarah-Jane Dawson; Jonine Figueroa; Jolanta Lissowska; Louise Brinton; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Angela Cox; Ian W Brock; Simon S Cross; Malcolm W Reed; Fergus J Couch; Janet E Olson; Peter Devillee; Wilma E Mesker; Caroline M Seyaneve; Antoinette Hollestelle; Javier Benitez; Jose Ignacio Arias Perez; Primitiva Menéndez; Manjeet K Bolla; Douglas F Easton; Marjanka K Schmidt; Paul D Pharoah; Mark E Sherman; Montserrat García-Closas
Journal:  J Pathol Clin Res       Date:  2014-12-04

10.  WNT8B as an Independent Prognostic Marker for Nasopharyngeal Carcinoma.

Authors:  Chawalit Ngernsombat; Pongphol Prattapong; Noppadol Larbcharoensub; Krittika Khotthong; Tavan Janvilisri
Journal:  Curr Oncol       Date:  2021-07-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.